Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0752347 (
Dementia with Lewy bodies
)
1,653
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alzheimer's disease (AD) and neocortical
Lewy body disease
(
LBD
) are the most common neurodegenerative dementias, with no available curative treatment. Elucidating pathomechanism and identifying novel therapeutic targets are of paramount importance.
Lemur tyrosine kinase 2
(
LMTK2
) is involved in several physiological and pathological cellular processes. Herewith a neuropathological characterization is presented in AD and neocortical
LBD
samples using chromogenic and fluorescent
LMTK2
immunohistochemistry on post-mortem brain tissues and compared them to age-matched controls (CNTs).
LMTK2
immunopositivity was limited to the neuronal cytoplasm. Neurons, including tau-positive tangle-bearing ones, showed decreased chromogenic and immunofluorescent labelling in AD in every cortical layer compared to CNT and neocortical
LBD
. Digital image analysis was performed to measure the average immunopositivity of groups. Mean grey values were calculated for each group after measuring the grey scale
LMTK2
signal intensity of each individual neuron. There was significant difference between the mean grey values of CNT vs. AD and neocortical
LBD
vs. AD. The moderate decrease in neocortical
LBD
suggests the effect of coexisting AD pathology. We provide neuropathological evidence on decreased neuronal
LMTK2
immunolabelling in AD, with implications for pathogenesis.
...
PMID:Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. 3174 22